These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9637307)

  • 1. Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats.
    Watari T; Kaneshima T; Tsujimoto H; Ono K; Hasegawa A
    J Vet Med Sci; 1998 May; 60(5):657-9. PubMed ID: 9637307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of branch retinal arterial occlusion with sodium ozagrel, a thromboxane A2 synthetase inhibitor.
    Kato H; Emura S; Takeuchi N; Enoki M; Oogushi K; Takashima T; Ohmori K; Saito I
    J Int Med Res; 1997; 25(2):108-11. PubMed ID: 9100166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of a thromboxane-synthetase inhibitor in patients with chronic persistent coughing and no airwayhyperresponsiveness].
    Nishi K; Mizuguchi M; Tachibana H; Watanabe K; Ooka T; Fujimura M; Matsuda T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Sep; 35(9):927-33. PubMed ID: 9396248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis.
    Fischer Y; Ritz S; Weber K; Sauter-Louis C; Hartmann K
    J Vet Intern Med; 2011; 25(6):1270-6. PubMed ID: 22092616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of acute phase proteins in differentiating between feline infectious peritonitis and other diseases in cats with body cavity effusions.
    Hazuchova K; Held S; Neiger R
    J Feline Med Surg; 2017 Aug; 19(8):809-816. PubMed ID: 27432437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chylous abdominal effusion in a cat with feline infectious peritonitis.
    Savary KC; Sellon RK; Law JM
    J Am Anim Hosp Assoc; 2001; 37(1):35-40. PubMed ID: 11204475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor.
    Kim Y; Liu H; Galasiti Kankanamalage AC; Weerasekara S; Hua DH; Groutas WC; Chang KO; Pedersen NC
    PLoS Pathog; 2016 Mar; 12(3):e1005531. PubMed ID: 27027316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis.
    Pedersen NC; Kim Y; Liu H; Galasiti Kankanamalage AC; Eckstrand C; Groutas WC; Bannasch M; Meadows JM; Chang KO
    J Feline Med Surg; 2018 Apr; 20(4):378-392. PubMed ID: 28901812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thromboxane A2 synthetase inhibitor in asthma therapy].
    Machida K; Takagi K; Horiba M
    Nihon Rinsho; 1996 Nov; 54(11):3034-9. PubMed ID: 8950950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride, for preeclampsia.
    Seki H; Kuromaki K; Takeda S; Kinoshita K; Satoh K
    Hypertens Pregnancy; 1999; 18(2):157-64. PubMed ID: 10476617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and laboratory features of cats with feline infectious peritonitis--a retrospective study of 231 confirmed cases (2000-2010).
    Riemer F; Kuehner KA; Ritz S; Sauter-Louis C; Hartmann K
    J Feline Med Surg; 2016 Apr; 18(4):348-56. PubMed ID: 26185109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thromboxane A2 synthetase inhibition suppresses cough induced by angiotensin converting enzyme inhibitors.
    Umemura K; Nakashima M; Saruta T
    Life Sci; 1997; 60(18):1583-8. PubMed ID: 9126880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a selective thromboxane A2 synthetase inhibitor on the systemic changes induced by circulating pancreatic phospholipase A2.
    Motoyoshi M; Sugiyama M; Atomi Y; Kimura W; Nagawa H
    J Gastroenterol; 2006 Nov; 41(11):1094-8. PubMed ID: 17160520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis.
    Ritz S; Egberink H; Hartmann K
    J Vet Intern Med; 2007; 21(6):1193-7. PubMed ID: 18196725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A thromboxane A2 synthetase inhibitor as an anticoagulant for left ventricular assist devices.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 1997; 43(5):M452-6. PubMed ID: 9360083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis.
    Ishida T; Shibanai A; Tanaka S; Uchida K; Mochizuki M
    J Feline Med Surg; 2004 Apr; 6(2):107-9. PubMed ID: 15123155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis.
    Pedersen NC; Perron M; Bannasch M; Montgomery E; Murakami E; Liepnieks M; Liu H
    J Feline Med Surg; 2019 Apr; 21(4):271-281. PubMed ID: 30755068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus.
    Addie DD; Toth S; Murray GD; Jarrett O
    Am J Vet Res; 1995 Apr; 56(4):429-34. PubMed ID: 7785816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. Comparative study with norphenazone, a free-radical scavenger.
    Imamura T; Kiguchi S; Kobayashi K; Ichikawa K; Yamazaki Y; Kojima M
    Arzneimittelforschung; 2003; 53(10):688-94. PubMed ID: 14650360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical symptoms and diagnosis of feline infectious peritonitis].
    Hirschberger J; Hartmann K; Wilhelm N; Frost J; Lutz H; Kraft W
    Tierarztl Prax; 1995 Feb; 23(1):92-9. PubMed ID: 7792783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.